Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research of oral prodrugs:opportunities and challenges

( views:177, downloads:53 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 4

DOI:: 10.3321/j.issn:0513-4870.2008.04.003

Key Word:: 口服吸收;靶向前药;肽类转运器

Abstract：前药研究是提高生物药剂学分类系统中第Ⅲ和Ⅳ类药物口服吸收的有效途径之一.本文综述了近年来口服前药研究的进展,主要包括经典前药设计和靶向前药设计.经典前药设计重在改善母体药物的油水分配系数或减少药物的代谢.靶向前药设计重在主动利用胃肠道的生理特性靶向组织、酶及肠内流转运器,其中靶向小肠内流转运器-肽类转运器的口服前药成为目前研究的热点.前药研究还面临选题,设计和体内研究等方面的挑战.

Reference

[1]Ganapathy ME,Brandsch M,Leibach FH,etc.Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2.[J].1995,270(43).
[2]Nakamura M,Yasuhara A,Fukasawa Y,etc.In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo(3.1.0)hexane-2,6-dicarb oxylic Acid), a potent metabotropic glutamate receptor antagonist.[J].2006,34(3).
[3]Han H,Covitz KM,Rhie JK,etc.5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.[J].1998,15(8).
[4]Cho H,Chung Y.Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs.[J].2004,27(6).
[5]Korczyn AmosD,Giladi Nir,Honigman Silvia,etc.Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.[J].2002,17(2).
[6]Borchardt RT.Optimizing oral absorption of peptides using prodrug strategies.[J].1999,62(1/2).
[7]Dack K,Beaumont K,Webster R,etc.Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.[J].2003,4(6).
[8]Terada T,Hashimoto Y,Saito H,etc.Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.[J].2000,440(5).
[9]Yoshigae Y,Aso T,Otagiri M,etc.Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.[J].1998,62(14).
[10]Nicholas Bodor,Peter Buchwald.Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems[J].1999,36(2-3).
[11]W B, Abrams,R O, Davies,H J, Gomez.Clinical pharmacology of enalapril.[J].1984,2(2).
[12]J, Van Gelder,M, Shafiee,E, De Clercq,etc.Species-dependent and site-specific intestinal metabolism of ester prodrugs.[J].2000,205(1-2).
[13]Fahr A,Liu X.Drug delivery strategies for poorly water-soluble drugs.[J].2007,4(4).
[14]Stella VJ,Nti-Addae KW.Prodrug strategies to overcome poor water solubility.[J].2007,59(7).
[15]Englund G,Rorsman F,Ronnblom A,etc.Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells.[J].2006,29(3/4).
[16]Borchardt RT,Liederer BM.Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human.[J].2005,94(10).
[17]Higuchi T,Katoh M,Takeuchi T,etc.Species differences of inhibitory effects on P-glycoprotein-mediated drug transport.[J].2007,96(6).
[18]Suzuyama N,Asahi S,Takeuchi T,etc.Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.[J].2006,95(12).
[19]Testa B.Prodrug research: futile or fertile?[J].2004,68(11).
[20]Rubio Aliaga I,Daniel H.Mammalian peptide transporters as targets for drug delivery.[J].2002,23(9).
[21]Toshiya Minagawa,Yoshiro Kohno,Toshio Suwa,etc.Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases[J].1995,49(10).
[22]Van-den-Mooter G.Colon drug delivery.[J].2006,3(1).
[23]Augustijns P,Tack J,Brouwers J.In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.[J].2007,336(2).
[24]Pauletti, G. M.,Gangwar, S.,Siahaan, T. J.,etc.Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies[J].1997,27(2).
[25]L. M. Beauchamp,G. F. Orr,P. de Miranda,etc.Amino Acid Ester Prodrugs of Acyclovir[J].1992,3(3).
[26]A, Tunek,E, Levin,L A, Svensson.Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro.[J].1988,37(20).
[27]D M, Lambert.Rationale and applications of lipids as prodrug carriers.[J].2000,11 Suppl 2.
[28]Saito H,Inui KI,Terada T,etc.Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2.[J].1999,291(2).
[29]Gordon L. Amidon,Peter Ettmayer,Bernd Clement,etc.Lessons Learned from Marketed and Investigational Prodrugs[J].2004,47(10).
[30]Mitra AK,Jain R,Mandava NK,etc.Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.[J].2007,336(2).
[31]Eriksson AH,Nielsen CU,Frokjaer S,etc.Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption.[J].2004,21(1).
[32]PE Williams,AN Brown,S Rajaguru,etc.The pharmacokinetics and bioavailability of cilazapril in normal man.[J].1989,27(S2).
[33]Isabel, Gomez-Orellana.Strategies to improve oral drug bioavailability.[J].2005,2(3).